Bias in research and conflict of interest: Why should we care?

International Urogynecology Journal

Volumn 18, Issue 3, 2007, Pages 241-243

  Dietz, H P ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DARIFENACIN; DULOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUROLEPTIC AGENT; ROFECOXIB; SOLIFENACIN; THIAZIDE DIURETIC AGENT; TOLTERODINE;

CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; CONFLICT OF INTEREST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL LITERATURE; NOTE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; SYSTEMATIC ERROR;

EID: 34248636494     PISSN: 09373462     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00192-006-0236-1     Document Type: Note

References (29)

1. Coyle SL (2002) Ethics, Human Rights Committee ACoP-A. Physician-industry relations. Part 1: Individual physicians. Ann Intern Med 136(5):396-402
2. Korn DMD (2002) Industry, academia, investigator: Managing the relationships. Acad Med 77(11):1089-1095 (November)
3. Mathews W (2005) A ghost story: At medical journals, writers paid by industry play big role. Wall Street J A1 (Dec 13)
4. Kassirer J (2006) Physicians on the take. MedGenMed 8(1):74
5. Bhandari M, Busse JW, Jackowski D et al (2004) Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials (see comment). CMAJ Can Med Assoc J 170(4):477-480
6. Montgomery JH, Byerly M, Carmody T et al (2004) An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin Trials 25(6):598-612
7. Buchkowsky SS, Jewesson PJ (2004) Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacother 38(4):579-585
8. Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA (2005) Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatr 162(10):1957-1960
9. Goetzsche P (2005) Research integrity and pharmaceutical industry sponsorship. Med J Aust 182(11):549
10. Gibbons R, Landry F, Blouch D et al (1998) A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts. J Gen Intern Med 13:151-154
11. Rogers W, Mansfield P, Braunack-Mayer A, Jureidini J (2004) The ethics of pharmaceutical industry relationships with students. Med J Aust 180:411-414
12. Andersen NV (2006) Gunnar lose vs. Yamanouchi. Ugeskrift for Laeger 168(6):546
13. Brown AJ (2001) Therapeutic uses of vitamin D analogues. Am J Kidney Dis 38(Suppl 5):S3-S19
14. Choudhry NK, Stelfox HT, Detsky AS (2002) Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 287(5):612-617
15. Moynihan R (2003) The making of a disease: Female sexual dysfunction. Br Med J 326:45-47
16. Moynihan R, Cassels A (2005) Selling sickness: How drug companies are turning us all into patients. G. Allen, Sydney, Australia
17. N.N. World Association of Medical Editors Recommendations on Publication Ethics Policies for Medical Journals, 2006 at: http://www.wame.org/, accessed 15.5.06
18. N.N. Uniform Requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication: International Committee of Medical Journal Editors, 2006, at: http://www.icmje.org/, accessed 15.5.06
19. Korn, D. and S. Ehringhaus, Principles for strengthening the integrity of clinical research. 2006, Public Library of Science at: http://www.plosclinicaltrials.org
20. N.N. World Medical Association Declaration of Helsinki, 2004, at: http://www.wma.net/e/policy/b3.htm., accessed 15.5.06
21. 4th Annual Patient Recruitment for Clinical Trials. 2006: New York, at: www.marcusevansbb.com/recruitment, accessed 10.6.06
22. The Allhat Officers and Coordinators for the Allhat Collaborative Research Group. Major outcomes in High-Risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA, 2002(Dec 18): P. 2981
23. Liebermann J, Stroup T, McEvoy J et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209-23
24. Angell M (2004) The truth about the drug companies: How they deceive us and what to do about it. Random House, New York
25. Curfman G, Morrissey S, Drazen J (2006) Expression of concern reaffirmed. N Engl J Med 354(11):1193
26. Moynihan R (2002) Alosetron: A case study in regulatory capture, or a victory for patients' rights? Br Med J 325:592-595
27. Lievre M (2002) Alosetron for irritable bowel syndrome. Br Med J 325:555-556
28. Horton R (2001) Lotronex and the FDA: A fatal erosion of integrity. Lancet 357:1544-1545
29. Fontanarosa PB, Flanagin A, DeAngelis CD (2005) Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded studies. JAMA 294:110-111 (July 6)